Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B.
Damsky W, et al. Among authors: daccache j.
Nat Commun. 2022 Jun 6;13(1):3140. doi: 10.1038/s41467-022-30615-x.
Nat Commun. 2022.
PMID: 35668129
Free PMC article.
Clinical Trial.